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1. Introduction  
Heart failure is now acknowledged to be the most common malignant disease in 
industrialized countries, with advanced heart failure having a worse prognosis than most 
forms of cancer (Garg, Yusuf 1993). Advances in pharmacological treatment have helped 
patients in all stages of systolic dysfunction, even those with NYHA IV symptoms (the 
Captopril-Digoxin Multicenter Research Group 1988, Packer et al. 1996, the RALES 
Investigators 1996). The Working Group on Heart Failure of the European Society of 
Cardiology has promoted a number of initiatives aimed at improving the treatment of heart 
failure (ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 
2008). 
Despite advances in pharmacological treatments aimed at a neurohormonal blockade for 
heart failure, there is still a growing number of patients with advanced symptoms who 
suffer significant morbidity and mortality. 
 Mechanical stresses on the myocardium (increased preload and afterload) and chronic 
neurohormonal activation conspire to propagate the maladaptive ventricular remodeling 
responsible for the insidious nature of heart failure. Recent studies suggest that further 
pharmacological neurohormonal blockade may be neither safe nor effective (Mann 2004). 
This finding has led to the concept that the limit to which neurohormonal and cytokine 
mechanisms can be blocked in heart failure patients has already been reached (Cohn, 
Tognoni 2001). The problem of how to treat patients worldwide who develop advanced 
heart failure despite optimal medical therapy has not yet been resolved (Gronda, Vitali 
1999). 
Transplantation provides the most effective therapy for this condition, but the shortage of 
donor organs  results in <10% of potential recipients actually receiving a transplant (Deng et 
al. 2001). This situation has forced scientists to search for alternative methods of treatment. 
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At present end-stage chronic heart failure is a significant clinical problem as well as a subject 
of scientific interest. Transplant candidates whose disease reaches its final stage before an 
appropriate donor heart becomes available might be considered eligible for temporary or 
permanent mechanical circulatory support (MCS). This is why ventricular assist devices 
(VADs) capable of completely supporting the circulation are taking on an increasingly 
important role in heart failure therapy. The concept of circulatory assistance is not new. The 
need for such temporary support for hours or days has been recognized for over 60 years 
and still exists (Norman 1974). It is recognized that device-based approaches, ranging from 
the use of devices for monitoring patient status in order to anticipate exacerbation of 
congestive heart failure and preemptively adjust therapy to the application of devices for 
supporting pre-terminal patients with end-stage disease, will assume an increasingly 
important role in treating the growing number of patients with advanced heart failure 
(Kantrowitz et al. 1968). Mechanical circulatory support was first used clinically in 1953 with 
the implementation of cardiopulmonary bypass (Gibbon 1954). This breakthrough led to 
numerous surgical treatments for a variety of cardiac disorders. The success of 
cardiopulmonary bypass stimulated research into other innovative techniques for 
supporting the circulation. Counterpulsation with the intra-aortic balloon pump (IABP) was 
first applied clinically in 1967 to support patients with acute heart failure (Kantrowitz et al. 
1968 ). From 1953 congestive heart failure patients were occasionally supported temporarily 
by cardiopulmonary bypass (Dennis 1966), an implantable ventricular assist device (VAD) 
(De Bakey et al. 1966) or a totally artificial heart (TAH) (Cooley et al. 1969). Although the 
overall success rate was limited, this early experience did prove that mechanical circulatory 
support could adequately sustain a patient’s circulation until cardiac function recovered or a 
donor heart could be obtained. In the early 1980s the introduction of cyclosporine-based 
immunosuppression allowed heart transplantation to become a widely accepted therapeutic 
alternative. During the same decade clinical trials were initiated to evaluate the safety and 
efficacy of MCS systems in supporting terminally ill transplant candidates until a suitable 
donor heart could be found. VADs are important bridges to cardiac transplantation. The 
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart 
Failure (REMATCH) trial revealed that they could be used as long-term destination therapy 
for non-transplant candidates (Rose et al., 1999). The use of a wearable ventricular assist 
device (VAD) in the treatment of advanced heart failure has steadily increased since 1993, 
when these devices became generally available. Since this time there has been rapid 
progress in the development of left ventricular assist device technology and artificial hearts.  
2. VADs — indications for support 
Patients with end-stage heart failure have a poor quality of life, a very high mortality rate, 
and are potential candidates for implantation of a ventricular assist device (VAD). Although 
cardiac transplantation (CTX) is associated with high 1- and 10-year survival rates, organ 
supply is limited. The technical improvements and proven success of implantable VADs 
have made it a reasonable treatment option in these patients, either as a bridge to cardiac 
transplantation or as destination therapy – Table 1 (2010 Focused Update of ESC guidelines 
on device therapy in heart failure). 
Mechanical circulatory support is life saving in patients who fail to improve or stabilize with 
intravenous inotropes or vasodilators, IABP support and mechanical ventilation.  
Hemodynamic criteria for VAD insertion are as follows (Oz et al., 1995): 
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- cardiac index < 2 L/min/m2; 
- systolic blood pressure < 90 mm Hg; 
- pulmonary capillary wedge > 20 mm Hg; 
- urine output < 20 mL/h; 
when these are found despite pharmacological support, optimal fluid loading and use of 
IABP as appropriate. 
Patient selection for VAD is crucial. Most patients are on continuous inotropic support. 
Patients with severe renal, pulmonary, or hepatic dysfunction as well as patients with active 
infection, carcinoma with metastases, significant blood dyscrasias, cerebral vascular disease 
or cardiogenic shock should not be considered as candidates (Lund et al., 2010). 
Each case is assessed individually and criteria are used as a guide only. Some patients have 
the VAD inserted prior to these criteria being met. In planning the application of the assist 
device we must decide whether one or both ventricles require support. Insertion of an 
implantable VAD complicated by early right ventricular failure has a poor prognosis and is 
largely unpredictable. Patients with risk factors for right ventricle dysfunction (the need for 
circulatory support, female gender, non-ischemic etiology) may best be treated with a 
biventricular assist device or a TAH. The next questions arising are whether the VAD 
should be implanted as a bridge to transplantation or as destination therapy and how long 
mechanical support will be required. Selection of the appropriate device depends on a 
number of considerations, including the anticipated duration of patient support, the need 
for right-side support and the patient’s size. Excluding the strict contraindications to VAD, 
insertion is very important.  
 
Recommendations Patient population 
Class of 
recommendation
Level of 
evidence 
LVAD may be considered 
as destination treatment 
to reduce mortality 
NYHA functional class 
IIIB/IV 
LVEF≤25% 
Peak VO2<14 mL/kg/min 
IIb B 
LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; NYHA = New York 
Heart Association. 
Table 1. Recommendation in patients with severe heart failure ineligible for transplant (2010 
Focused Update of ESC guidelines on device therapy in heart failure).  
One recent study was conducted in 200 patients, who were randomized in a 2:1 ratio to a 
continuous-flow device (HeartMate I) or a pulsatile device (Slaughter et al., 2009) as 
destination therapy. Patients were in NYHA function class IIIB/IV with an LVEF of ≤25%. 
A peak VO2 of ≤14 mL/kg/min was an inclusion criterion in HEART MATE II but gas-
exchange data during exercise are not routinely available in clinical practice and may be 
inconclusive. The primary composite endpoint was, at 2 years, freedom from disabling 
stroke or reoperation to repair or replace the device. Secondary endpoints included 
actuarial survival. The mean age of the patients was 64 years, and the mean left 
ventricular ejection fraction was 17%. The primary endpoint was achieved in more 
patients with the continuous-flow device (46 vs. 11%, P < 0.001) and actuarial survival at 2 
years was higher (58 vs. 24%, P = 0.008). Another study examined 281 patients in whom 
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the continuous device was implanted as a bridge to cardiac transplantation (Pagani et al., 
2009). After 18 months, 222 patients (79%) underwent cardiac transplantation, left 
ventricular assist device removal for cardiac recovery, or required ongoing LVAD support 
(Drews et al., 2010). The INTERMACS registry, an National Institutes of Health (NIH)-
supported initiative, demonstrates that in practice ~10% of patients receiving an 
LVAD are not considered candidates for CTX at the time of implantation (Kirklin et al., 
2010).  
3. Patient selection and preoperative considerations 
The highest risk of death after ventricular assist device implantation is before hospital 
discharge. Thus, patient selection and the timing of implantation are two of the major 
determinants of success. Main selection criteria include assessment of the patient’s severity 
of illness and ability to successfully undergo the implant procedure. Preoperative selection 
criteria which predict successful outcome are difficult to evaluate. The selection of 
appropriate candidates with a potentially good outcome is of major importance in VAD 
implantation. 
Patients are assessed for appropriateness for LVAD support based on the degree of illness, 
ability to successfully undergo the operative procedure and ability to be discharged home 
with adequate family/caregiver support for long-term success. Mortality rates are high after 
implantation of a ventricular assist device, occurring mainly in the early phase post-implant 
during the time in the intensive care unit.  
4. Patient assessment before LVAD support 
The Heart Failure Survival Score (Aaronson et al., 1997) and the Seattle Heart Failure Model 
(Levy et al., 2006) estimate a heart failure patient’s expected survival during the next 1 to 2 
years on medical management and identify patients at high risk of death who might benefit 
from LVAD support. 
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 
registry, which follows all long-term mechanical circulatory support systems in the United 
States, has defined patient profiles that can help identify risks associated with the timing of 
implantation (Holman et al., 2009; Stevenson et al., 2009) – Table 2. The current 6-month 
survival data for patients receiving pulsatile LVADs indicate that patients in profile 1, 
cardiogenic shock, have the lowest survival, and those in profile 3, stable on inotropes, have 
the best survival (Kirklin et al., 2010).  
These data indicate that patients with cardiogenic shock may be too sick for permanent 
LVAD support. Thus, for these patients, consideration should be given to immediate 
stabilization with biventricular support, using temporary percutaneous or surgically placed 
systems or other appropriate treatments, to optimize their condition before implant surgery. 
This is especially true for the destination therapy indication because most patients can be 
stabilized and their risks assessed and reduced before implantation. Implantation of a long-
term LVAD should not be considered for patients with irreversible major end-organ failure, 
uncertain neurological status, severe hemodynamic instability, major coagulopathy, 
prolonged need for mechanical ventilation, sepsis, or right-heart failure (Slaughter et al. 
2010). 
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Profile Description Time to MCS 
1 “Crashing and burning”—critical cardiogenic shock Within hours 
2 
“Progressive decline”—inotrope dependence with continuing 
deterioration. 
Within a few days 
3 
“Stable but inotrope dependent”—describes clinical stability 
on mild-to-moderate doses of intravenous inotropes (patients 
stable on temporary circulatory support without inotropes 
are within this profile). 
Within a few 
weeks 
4 
“Recurrent advanced heart failure”—“recurrent” rather than 
“refractory” decompensation 
Within weeks to 
months 
5 
“Exertion intolerant”—describes patients who are 
comfortable at rest but are exercise intolerant. 
Variable 
6 
“Exertion limited”—describes a patient who is able to do 
some mild activity but fatigue results within a few minutes of 
any meaningful physical exertion. 
Variable 
7 
“Advanced NYHA III”—describes patients who are clinically 
stable with a reasonable level of comfortable activity, despite 
a history of previous decompensation that is not recent. 
Not a candidate 
for MCS 
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; MCS, 
mechanical circulatory support; NYHA, New York Heart Association. 
Table 2. INTERMACS Patient Profiles and Timeframe for Initiating Mechanical Circulatory 
Support (Holman et al., 2009; Slaughter et al. 2010).  
5. Risk factors for operative mortality 
Lietz and Miller (Lietz et al., 2007) analyzed preoperative clinical data from 222 patients 
who received the HeartMate XVE LVAD for destination therapy. They established a risk 
scoring system to estimate survival after implantation. The multivariate analysis produced 9 
risk factors for 90-day mortality, which were assigned a weighted score (Table 3). The 
cumulative scores for each patient were then used to determine the risk category: 0 to 8, low 
risk; 9 to 16, medium risk; 17 to 19, high risk; and >19 very high risk. The survival to 
hospital discharge was 87.5%, 70.5%, 26%, and 13.7% for the low-, medium-, high-, and very 
high-risk groups, respectively.   
 
Risk factor  Score 
Platelet count  < 148 x 103/µL  7 
Serum albumin < 3.3 g/dL 5 
International normalization ratio > 1.1  4 
Vasodilator therapy  4 
Mean pulmonary artery pressures < 25 mm Hg  3 
Aspartate aminotransferase  > 45 U/mL  2 
Hematocrit < 34% 2 
Blood urea nitrogen > 51 mg/dL 2 
No intravenous inotropes  2 
Table 3. Risk Factors for 90-Day Mortality and the Weighted Scores (Lietz et al., 2007) 
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In 1995, Oz et al. found 7 preoperative factors that predicted poor outcome in a group of 56 
patients. These consisted of urine output <30 mL/h, central venous pressure >16 mm Hg, 
mechanical ventilation, prothrombin time (PT) >16 seconds, re-operation, leukocyte count 
>15,000/mm3 and temperature >101.5°F. However, they used only a first-generation device 
and prediction of urine output <30 mL/h takes at least 1 hour (Oz et al. 1995). 
 Therefore, this score was revised by Rao et al. based on 130 patients and more easily 
obtained and quickly accessible parameters (ventilation, post-cardiotomy, pre-VAD, CVP 
>16 mm Hg, prothrombin time > 16 seconds) (Rao et al. 2003). In 2001, Deng et al. reviewed 
the Novacor registry data in 464 patients and highlighted 5 parameters – respiratory failure 
with septicemia, preexisting right heart failure, age >65 years, acute post-cardiotomy, and 
acute infarction – predicting mortality during VAD support (Deng et al., 2001). In 2004, 
Chen et al. showed that lactate, and lung and kidney injury are predictive of poor outcome 
among patients on extracorporeal membrane oxygenation (ECMO) support that was 
switched to VAD support (Chen et al., 2004). In addition, some studies showed that 
predictors of poor outcome were similar in total artificial heart or biventricular VAD 
implantation as compared with VAD implantation. Scientists also tried to use existing 
intensive care scores, such as the APACHE II score, to predict VAD mortality (Gracin et al., 
1998). However, these already existing scores, which attempt to predict mortality after VAD 
implantation, are based on first-generation pulsatile devices and not on modern second- or 
third-generation devices, and they assess overall death after VAD as the primary outcome. 
They do not specifically focus on mortality in the intensive care unit, which is especially 
dependent on preoperative clinical status. Klotz et al. implemented a pre-operative risk 
score to predict mortality in the intensive care unit after VAD implantation by using easily 
obtained and quickly accessible clinical parameters (Klotz et al., 2010).  
By focusing on mortality in the intensive care unit, they tried to evaluate preoperative 
patients who were too sick for mechanical support and may not have survived their stay in 
the ICU. In 241 VAD patients, 100 preoperative markers were related to mortality in the ICU 
using univariate analysis and ROC curves, followed by multinomial logistic regression 
analyses. The mortality rate in the ICU was 32.0%.  
The parameters with the highest negative impact on survival in the ICU were: age>50 years, 
ischemic cardiomyopathy, re-do surgery, on ECMO, on IABP, previous cardiac surgery, 
ventilation, emergency implant, inotropic support, renal replacement therapy, preoperative 
resuscitation, transfusion, blood urea nitrogen >40 mg/L, creatinine>1.5 mg/dL, lactate >3 
mg/dL, platelets <100 x 1000/µL, whole blood cell count >13,000/µL, C-reactive protein > 8 
mg/dL, hemoglobin <12 g/dL, hematocrit <35%, lactate dehydrogenase >500 U/liter, 
creatinine kinase>200 U/liter, troponin >20 ng/mL.  
The risk for mortality in the intensive care unit was as follows: low <15 points, medium 16-
30 points, high >30 points.  
This score distinguishes clearly between the different urgencies of VAD implantation – 
Figure 1.  
These observations suggest that in-hospital mortality can be predicted preoperatively with 
easily obtained and quickly accessible parameters. Patients who initially present as high-risk 
or very high-risk are most likely to benefit from a period of optimization therapy to attempt 
to lower their risk score (for example: coagulation, nutrition, renal function, right atrial 
pressure) and then become more suitable candidates for LVAD support. Patients with a low 
risk should be considered for prompt elective LVAD implantation before their condition 
worsens. 
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Fig. 1. Mortality in the ICU, depending on VAD implant urgency. Post-cardiotomy is 
defined as patients with unsuccessful weaning from bypass and on ECMO support.  
Pre-implant optimization of comorbid conditions is very important in minimizing the 
incidence and severity of postoperative adverse events and for enhancing survival. The 
most influential pre-implant measures are: 
• Improving nutritional status 
Malnutrition is very common in patients with advanced heart failure. If not improved, it 
increases the risk of infection, decreases the body’s ability to recover after surgery, and is 
generally associated with poor outcomes. Studies have shown that cachexia (BMI <22 
kg/m2) is associated with a high risk for peri-operative death, often due to infection (Manop 
et al., 2009; Holdy et al., 2005).  
Markers of severe malnutrition include a BMI <20 kg/m2, albumin <3.2 mg/dL, pre-
albumin <15 mg/dL, total cholesterol <130 mg/dL, lymphocyte count <100, and purified 
protein derivative skin test anergy. The nutrition needs to be improved before LVAD 
implantation (a pre-albumin level >15 mg/dL). For patients with pre-albumin <15 mg/dL, 
enteral feedings are often helpful preoperatively and should be continued after implantation 
until the patient is taking adequate nutrition. 
It is equally important to maintain adequate nutrition after the implant surgery. Data from 
Lockard et al. have shown that patients with a pre-albumin level of <15 mg/dL at 2 weeks 
after LVAD implantation had a significantly greater risk of dying in the hospital (Lockard et 
al., 2009). 
• Lowering pulmonary vascular resistance to optimize right-heart function and to 
reduce right atrial pressure and secondary hepatic congestion  
Left ventricular unloading with a LVAD should decrease right ventricular after-load by 
reducing pulmonary artery pressures (PAPs) (Farrar et al. 1985). 
However, mechanical support may increase systemic venous return to a myopathic right 
heart that is unable to accommodate the additional volume. Furthermore, reduction in left 
ventricle pressure can cause the interventricular septum to shift leftward, potentially 
causing disadvantageous geometric changes in the right ventricle that reduce the septal 
contribution to right ventricle stroke volume and exacerbate tricuspid regurgitation (Farrar 
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et al. 1985). Importantly, right ventricle failure after implantation can be anticipated 
preoperatively and improved with various therapies that optimize its function. An analysis 
of 484 patients in the HeartMate II Bridge to Transplant clinical trial demonstrated the 
following independent predictors of right ventricle failure: preoperative ventilatory support, 
central venous pressure (CVP)/pulmonary capillary wedge pressure ratio >0.63, and blood 
urea nitrogen >39 mg/dL (Kormos et al., 2010).  
Univariate predictors also included a right ventricular stroke work index (RVSWI) <300 
mm Hg × mL/m2, central venous pressure (CVP) >15 mm Hg, elevated blood urea nitrogen 
(BUN), and elevated white blood cell count. The HeartMate II trial found no difference in 
the incidence of right ventricular failure in heart failure patients with non-ischemic vs 
ischemic etiology. 
Other signs of poor right ventricle function can be found with pre-implant 
echocardiography. Close attention should be paid to RV size, with particular caution 
extended to patients who have a dilated, poorly contracting right ventricle. Severe tricuspid 
regurgitation also can be associated with early postoperative RV failure. Some have 
advocated repair of the tricuspid regurgitation at the time of LVAD implantation if its 
severity is judged to be more than moderate, either preoperatively or intraoperatively by 
echocardiogram. 
Patients at risk for postoperative right ventricle failure should not necessarily be eliminated 
from LVAD support. However, the implanting team should promptly treat RV failure using 
pharmacotherapeutics and mechanical RV support, as appropriate or needed (Slaughter et 
al. 2010). 
• Aggressively managing volume to minimize right ventricular workload and hepatic 
congestion 
A pulmonary artery catheter 24 hours before implantation is useful in most patients to 
assess the cardiac index and volume status as well as to guide diuretic, vasodilator, and 
inotropic support. One of the main objectives is to reduce the central venous pressure (CVP) 
to 15 mm Hg or less. This will aid in reducing the right ventricle workload and minimizing 
hepatic congestion and the possible need for a right ventricular assist device (RVAD). When 
the CVP exceeds 20 mm Hg, ultrafiltration and inotrope and vasodilator therapy should be 
used; also consider temporary RVAD support. Increasing the cardiac index with 
vasodilators, inotropes, and using an IABP will improve conditions for all organ systems. 
Medications that can lower pulmonary vascular resistance (PVR) and improve the cardiac 
index before surgery may be beneficial in reducing the incidence of right ventricular failure 
after implantation (Galie et al., 2005; Klodell et al., 2007).  
Medications that have been shown to reduce PVR include angiotensin-converting enzyme 
(ACE) inhibitors, hydralazine, nitroglycerin, nitroprusside, nitric oxide, sildenafil, 
prostaglandins, and inotropes (milrinone and dobutamine). 
• Optimizing coagulation 
Preoperative abnormal coagulation is common in heart failure patients due to hepatic 
dysfunction and the use of anticoagulant or antiplatelet medications. When possible, these 
medications should be stopped before implantation. Vitamin K may be given to reverse the 
effects of warfarin. For patients who are at high risk of preoperative thrombosis, a 
continuous infusion of heparin should be given. Because the continuous-flow left 
ventricular assist device requires systemic anticoagulation, its use in patients with a history 
of gastrointestinal (GI) bleeding should be carefully considered. Active GI blood loss should 
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be assessed for 3 to 4 weeks before left ventricular assist device implantation (Slaughter et 
al. 2010). 
• Optimizing renal, hepatic, pulmonary and neurological function 
Renal dysfunction is a predictor of adverse outcomes in LVAD-supported patients (Sandner 
et al., 2009; Ma et al., 2008; Butler at al. 2006). Patients in the HeartMate II Bridge to 
Transplant trial were excluded if their creatinine level was <3.5 mg/dL or if they needed 
chronic dialysis; 11% of patients had some degree of renal dysfunction after implantation 
(Miller et al., 2007).  
Optimizing renal function preoperatively entails measures to increase renal perfusion and 
reduce central venous pressure. Renal dysfunction generally improves after LVAD 
implantation if decreased glomerular filtration rate is due to low cardiac output before 
implantation. 
Liver dysfunction is associated with greater need for intraoperative and perioperative blood 
transfusion, which can result in worsened right-heart function and the need for RVAD 
support. Many centers screen patients with clinical evidence of significant right heart failure 
or serological evidence of hepatic dysfunction using hepatic ultrasound imaging or liver 
biopsy to rule out cirrhosis. 
As with renal function, there is evidence that hepatic function improves after implantation 
of a continuous-flow LVAD (Radovancevic et al., 2007; Letsou et al., 2003).  
Specific management strategies should be initiated to improve hepatic function before an 
LVAD is implanted in individuals with abnormal values for prothrombin time (PT), partial 
thromboplastin time (PTT), and international normalized ratio (INR). Right heart pressure 
and pulmonary vascular resistance should be decreased using combinations of drugs to 
reduce pre-load and after-load, ultrafiltration, or both. 
Patients with severe obstructive or restrictive pulmonary disease are not eligible for LVAD 
therapy. When pulmonary function testing can be performed reliably, and the forced vital 
capacity, forced expiratory volume at 1 second, and carbon monoxide diffusing capacity are 
all less than 50%, exclusion from LVAD implantation should be considered. 
Patients with neurological or psychiatric disease that compromises their ability to use and 
care for external system components, or to ambulate and exercise, are not appropriate 
candidates for LVAD support (Tylus-Earl et al. 2009).  
Psychiatric disorders, drug abuse, and other psychosocial issues must be investigated to 
assess the patient’s ability to understand and comply with care instructions. 
All patients with an audible bruit or peripheral arterial disease, diabetes, or age >60 years, 
should undergo a carotid ultrasound study to rule out significant stenosis or the presence of 
unstable plaque. Patients with previous stroke also warrant computed tomography (CT) 
scan or magnetic resonance imaging (MRI) to establish a preoperative baseline study. 
Patients must have a reliable means of transportation for follow-up visits and a convenient, 
reliable telephone service to call for medical help in an emergency. 
• Treating any infection or providing prophylactic antibiotic therapy  
Patients with active systemic infection should not be considered for LVAD support because 
infection is one of 
the leading causes of morbidity and death. Implantation should be delayed for patients with 
localized infections that can be effectively treated, if clinically feasible. 
We should try to cope with patients with established or suspected infections, prolonged 
intubation, cutaneous lesions at surgical sites, or other comorbidities, including multisystem 
www.intechopen.com
 Ventricular Assist Devices 
 
78 
organ dysfunction, immunosuppression, poorly controlled diabetes, renal failure, 
malnutrition, or debilitation (Slaughter et al. 2010).   
6. Device selection 
Mechanical support can be applied short-term in an individual patient as a bridge to 
transplantation or can be applied long-term as in destination therapy. For example, if a 
patient with myocardial infarction and cardiogenic shock experiences a cardiac arrest that 
requires prolonged resuscitation, the heart failure specialist would know that percutaneous 
mechanical support could precede a potential LVAD until the neurological status is 
determined. If an LVAD is subsequently implanted, the patient’s candidacy for 
transplantation versus discharge and long-term LVAD maintenance therapy (i.e., destination 
therapy) must be considered.  
Numerous devices are now approved by the Food and Drug Administration (FDA) for 
therapy in acute heart failure and in chronic decompensated congestive heart failure – Table 4.  
 
Company Device Position 
Abiomed, Inc Abiocor Total Artificial Heart 
Total artificial 
heart 
MicroMed 
Technology, Inc 
MicroMed DeBakey Ventricular Assist 
Device - Child 
Left ventricle 
SynCardia Systems, 
Inc 
SynCardia CardioWest 
Total artificial 
heart 
Thoratec Corp 
HeartMate II Left Ventricular Assist 
Support 
HeartMate Implantable Pneumatic 
HeartMate Vented Electric 
HeartMate Extended Vented Electric  
Thoratec Implantable Ventricular Assist 
Device 
Thoratec Paracorporeal Ventricular Assist 
Device 
Left ventricle 
Left ventricle 
Left ventricle 
Left ventricle 
Left or right 
ventricle 
Left or right 
ventricle 
WorldHeart, Inc 
Novacor PC 
Novacor PC 
Left ventricle 
Left ventricle 
Table 4. Food and Drug Administration-Approved Durable Devices (Potential for Patient 
Discharge)  
These devices can be divided according to site of placement (commonly extra-, para- or 
intracorporeal) and type of flow generator system (centrifugal, axial or diaphragm).  
Intracorporeal ventricular assist device are presented in Figure 2.  
Device selection depends not only on specific patient characteristics and the pathology of 
the patient’s heart failure but also on device characteristics, device availability and the 
experience of the surgical team (D’Alessandro et al. 2002, Goldstein et al. 1998).  
Patients in profound cardiogenic shock require support to avoid permanent end-organ 
dysfunction and increase their chances of survival. The preferred devices are the ABIOMED 
BVS 5000 or Thoratec device. These devices may provide full biventricular support, re-
establishing near normal hemodynamics while myocardial recovery is awaited. If prolonged  
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Fig. 2. Intracorporeal ventricular assist devices.  
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support is expected, conversion to a longer-term device such as an implantable LVAD or 
TAH should be considered. The Thoratec device has the advantage of providing long-term, 
extracorporeal support. Device selection for long-term support is much more complicated 
and is often subjective and based on the surgeon’s experience. For smaller patients (body 
surface area < 1.5 m2) the Thoratec device and perhaps a continuous-flow pump are the only 
options (Delgado et al. 2002).  
7. Continuous versus pulsatile-flow pumps 
Long-term implantable mechanical circulatory assistance as a clinically viable entity started 
with the approval of the HeartMate XVE as a bridge to transplantation. Results of the 
REMACH trial led to the device being approved for destination therapy (Lietz et al., 2007).  
The other implantable pulsatile devices approved in the United States are the WorldHeart 
Novacor left ventricular assist device and SynCardia total artificial heart. These first-
generation pumps were designed to mimic nature and produce pulsatile blood flow. There 
has been much debate over the need for pulsatility. Animal data suggest that non-pulsatile 
flow might not deliver as much perfusion to the distal vasculature and might lead to 
weakening of the muscle in the walls of major arteries (Yada et al., 1999; Potapov et al., 
2000).  
The pulsatile devices are bulky as they have to at least be the size of the bladder 
displacement (usually 60 to 80 cc) and hence have to be placed in the pre- or intraperitoneal 
space. A diaphragm or sac is required to eject the blood and flexing of this biomaterial 
interface can lead to failure after millions of cycles. Mechanical energy is derived from a 
pusher plate-type motor, which has decreased device resistance. These technical limitations 
mandated by pulsatile devices have led to decreased reliability and durability and a high 
incidence of infections. Furthermore, the major surgery required for implantation increases 
the rate of bleeding, perioperative complications, length of hospital stay and need for 
rehabilitation.  
The next generation of devices consists of continuous-flow pumps. The HeartMate II device 
is approved as a bridge to transplant and destination therapy. The HeartWare HVAD, Jarvik 
2000, Trumo DuraHeart and Ventracor VentrAssist devices are in clinical trials. The 
Cleveland Clinic TAH (Fumoto et al. 2010; Fukamachi et al. 2010) can transition continuous 
flow principles to a TAH and allow the technology to be used in patients requiring 
biventricular support. Compared with previous pulsatile devices, continuous-flow pumps 
cannot completely decompress the left ventricle as the native heart must have some residual 
volume to prevent suction events. Therefore, the native heart continues to eject and this 
provides a moderate amount of pulsatility. This low level of pulsatility is apparently enough 
to increase end-organ perfusion and allow these patients to recover from chronic congestive 
heart failure. In many patients, this ejection occurs through the left ventricular assist device 
and the aortic valve can remain closed. They contain only one moving part, the rotor, which 
is why they tend to be much more reliable. Continuous-flow LVADs are also silent during 
operation and create minimal motion and vibration. These features make continuous-flow 
devices more suitable for use in patients with smaller body size. Because they are much 
smaller and do not have the constant motion caused by blood displacement, the infection 
rates have dramatically decreased (Miller et al. 2007; Bielecka et al., 2007).  
The trend in circulatory assistance is toward continuous-flow devices. They offer many 
advantages over the pulsatile devices in terms of size, reliability, durability and infection. 
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However, long-term results will need to be followed closely, specifically with regard to the 
perioperative period and the incidence of cerebrovascular accident despite appropriate 
anticoagulation (Jeevanandam 2010; Boyle 2009). 
Table 5 provides a general comparison of the 2 types of LVADs in clinical use.  
 
Attribute Pulsatile-flow VAD Continuous-flow VAD 
Type of pump Sac or diaphragm 
Centrifugal or axial flow by 
rotating impeller 
Main hemodynamic 
characteristics 
Intermittent unloading of 
ventricle; pulsatile arterial 
pressure; asynchronous 
with heart 
Continuous unloading of 
ventricle 
Physiological flow 
variables 
Pre-load dependant 
Pre-load and after-load 
dependant 
Mechanical flow variables 
Automatic or fixed rate and 
stroke volume capacity 
Set speed of the impeller 
rotation 
Size  
Large, intracorporeal 
devices limited to large 
patients, extracorporeal 
devices especially suited for 
smaller patients or for 
biventricular support 
Smaller, accommodates 
most patients, excluding 
infants 
Blood flow capacity Up to 10 liters/min Up to 10 liters/min 
Table 5. Comparison of pulsatile and continuous-flow ventricular assist devices (Slaughter 
et al. 2010).   
8. Axial and centrifugal pumps 
Continuous-flow ventricular assist devices use axial-flow or centrifugal-flow blood pumps. 
The most modern axial flow devices offer significant potential advantages over earlier 
devices, because they are smaller, simpler and less obtrusive to the patient, yielding a better 
quality of life. The blood flow is essentially non-pulsatile and pump output is dependent 
mainly on afterload. In addition, because of their smaller size, they can be used in smaller 
patients, including children (Frazier et al. 2005). The axial flow pumps in current use are: the 
MicroMed/DeBakey VAD (MM-D VAD) and the Jarvik 2000 Heart, which have certain 
similarities in design and function. The Jarvik 2000 Heart, in particular, has many 
advantages. Its implantation can be performed without median sternotomy, which makes 
the eventual transplantation operation easier. There is no inflow cannula, which rids the 
patient of the thrombotic and hemolytic problems encountered with inflow cannulae. 
Circulation to the coronaries, the brachiocephalic, the left carotid and the subclavian arteries 
is thus provided by retrograde flow. There is no need for an external pocket in the 
mediastinum or the peri-peritoneum, which decreases the risk of infection (Westaby et al. 
2000). The MicroMed/DeBakey VAD consists of a titanium inflow cannula that is inserted 
into the left ventricular apex and leads to the pump proper, which connects to the ascending 
aorta via a vascular graft. The pump is implanted through a median sternotomy in a small 
extracardiac pocket (Noon et al. 2000).  
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The HeartMate II device is an axial flow pump that has a spinning rotor as its only moving 
part and the direction of blood is parallel to the rotor. The HeartMate II has a left ventricular 
apical inflow cannula with a sintered titanium blood-containing surface. No compliance 
chamber or valves are necessary. The outflow cannula is connected to a Dacron graft, which 
is then anastomosed to the ascending aorta in a similar fashion to that achieved with the 
original HeartMate XVE. The pump is designed to deliver as much as 10 L/min of cardiac 
output and is placed either intraperitoneally or extraperitoneally (Delgado et al. 2005; Noon 
et al., 1999).  
The HeartMate II LVAD is shown in Figure 2. 
 
 
Fig. 3. The HeartMate II LVAD.  
HeartMate II has FDA approvals as bridge-to-transplant and destination therapy. 
Two other axial-flow pumps are: Incor (left ventricular assist device with magnetic bearing) 
and Synergy (left ventricular assist device with blood-immersed bearings). Centrifugal 
pumps use the pump mechanism of a standard heart bypass. In devices such as the HVAD, 
DuraHeart, Levacor VAD and EVAHEART LVAS the inflow and outflow of blood are in 
perpendicular directions (Bielecka et al. 2007).  
New centrifugal systems include the bearingless system. This drive system is magnetically 
coupled to an external power source and pump flow is related to rotation speed. The 
advantages of the centrifugal pump are simplicity of design, versatility and the relatively 
low costs of manufacture and operation. It can be used as a femoral-femoral bypass or as a 
left (right) ventricular-to-aortic (pulmonary artery) bypass. Its main disadvantages are the 
need for heparinization, difficulty in chest closure, the need for intensive monitoring and the 
inability to generate a pulsatile flow. The pump is used primarily as a bridge to recovery in 
cardiogenic shock. The total duration of support with a centrifugal pump is usually limited 
to no more than two to three weeks (Noon et al. 1999). 
The Interagency Registry For Mechanical Circulatory Support (INTERMACS) report 
examined the changing patterns of practice in the application of device type (continuous-
flow vs pulsatile) and device strategies during the past 3 years (Kirklin et al., 2010). 
The INTERMACS playing field changed dramatically in April 2008 when the HeartMate II 
axial flow pump (Thoratec) received FDA approval for clinical use as bridge-to-transplant 
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therapy in the United States. When continuous flow technology is routinely available for 
long-term destination therapy, and as multiple continuous-flow pumps are approved, 
INTERMACS offers a unique opportunity to compare and contrast these technologies in the 
setting of evolving indications, changing patient profiles, and refinement of device strategy 
in the developing landscape of mechanical circulatory support. 
This report focuses on the 1,092 patients who received primary left ventricular assist device 
implants among the total of 1,420 patients who received primary and secondary devices.  
The distribution of pre-implant device strategies continues to focus on bridging patients to 
cardiac transplantation with the device as a bridge to candidacy or bridge to transplant. The 
initial strategy was permanent in nearly 10% – Table 6.   
 
Pre-implant device strategy No. (N=1092) % 
Bridge to transplant  496 45.4 
Bridge to candidacy 458 41.9 
Planned destination therapy 100 9.2 
Bridge to recovery 25 2.3 
Rescue therapy 10 0.9 
Other 3 0.3 
Total 1092 100.0 
Table 6. Device strategy at Time of Implant of Primary LVAD (INTERMACS) (Kirklin et al., 
2010).  
According to INTERMACS data risk factors reflecting older age, greater severity of right 
ventricular failure and cardiogenic shock at implant predict a higher likelihood of early 
death among all LVAD patients. The use of a pulsatile pump was a risk factor for death in 
the constant phase. Because continuous-flow pumps have only accrued a mean follow-up of 
4.6 months, adverse events among pulsatile vs continuous-flow pumps during the first 6 
months after implantation were assessed. Generally, the events per 100 patient-months are 
importantly reduced in patients with continuous-flow devices versus pulsatile pumps for 
device malfunction, infection, hepatic dysfunction, and neurological events – Table 7. 
INTERMACS has analyzed the first 1000-plus patients with primary implantation of LVADs 
during a transitional period from pulsatile technology to continuous-flow pumps. The shift 
toward implantation of axial flow technology since its approval by the Food and Drug 
Administration is dramatic. This trend has been accompanied by continued fluctuation in 
the designation of the primary device strategy as bridge to transplant, bridge to candidacy 
and destination therapy (Kirklin et al., 2010). 
The use of mechanical device support in the congenital heart disease patient requires 
knowledge of anatomical and physiological factors such as body size, residual intracardiac 
shunts, the presence of a single ventricle, or venous anomalies and/or arterial anomalies that 
may impact the success of device implantation, and the effectiveness of the VAD support. 
Evidence-based clinical management of LVAD-supported patients is becoming increasingly 
important for optimizing outcomes. Patient and device selection, preoperative preparation 
and the timing of LVAD implantation are some of the most important elements critical to 
successful circulatory support and are principles universal to all devices.  
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Pulsatile 
(n = 406) 
Continuous 
(n = 548) 
Pulsatile / 
continuous Adverse event 
Events Rate Events Rate Ratio p-value 
Device malfunction 45 2.95 17 0.82 3.60 <0.0001 
Bleeding 369 24.22 360 17.41 1.39 <0.0001 
Cardiac/vascular 
  Right heart failure 
  Myocardial infarction 
  Cardiac arrhythmia 
  Pericardial drainage 
  Hypertension1  
  Arterial non-CNS thrombosis 
  Venous thrombotic event 
  Hemolysis 
 
48 
2 
154 
44 
75 
7 
38 
11 
 
3.15 
0.13 
10.11 
2.89 
4.92 
0.46 
2.49 
0.72 
 
46 
2 
218 
30 
17 
6 
32 
12 
 
2.23 
0.10 
10.54 
1.45 
0.82 
0.29 
1.55 
0.58 
 
1.41 
1.30 
0.96 
1.99 
6.00 
1.59 
1.61 
1.24 
 
0.05 
0.37 
0.65 
0.003 
<0.0001 
0.21 
0.03 
0.29 
  Infection 431 28.29 244 11.80 2.40 <0.0001 
Neurological dysfunction 66 4.33 40 1.93 2.24 <0.0001 
Renal dysfunction 63 4.14 45 2.18 1.90 0.0007 
Hepatic dysfunction 24 1.58 14 0.68 2.32 0.009 
Respiratory failure 121 7.94 89 4.31 1.84 <0.0001 
Wound dehiscence 8 0.53 9 0.44 1.20 0.34 
Psychiatric episode 43 2.82 38 1.84 1.53 0.03 
Total burden 1549 101.69 1219 58.96 1.72 <0.0001 
1  - with current reporting, identification of hypertension with continuous-flow pumps is unreliable. 
CNS  - central nervous system 
Table 7. Adverse event rates (events/100 patient months) in the first 12 months post-implant 
for primary LVADs (INTERMACS) (Kirklin et al., 2010).  
9. Intraoperative considerations 
Moderate to severe aortic insufficiency and mitral stenosis must be corrected during LVAD 
implantation. 
Inflow cannulas must be directed posteriorly toward the mitral valve. Obstruction may 
result if the cannula is directed or angled toward the septum or free wall or due to changes 
in position as the left ventricular chamber size is reduced over time. 
Proper placement of the percutaneous lead is important for long-term prevention of 
infection and damage to wires. Tunnel the percutaneous lead to maximize the amount of 
velour that is inside the body. It may be positioned in a gentle loop or arc, leaving some 
internal slack for accidental tugs in the perioperative period. 
Certain LVAD implant steps can be taken before initiation of cardiopulmonary bypass 
(CPB) to minimize CPB time: tunnel the percutaneous lead and anastomosis of the outflow 
graft to the ascending aorta. 
Before the patient is taken off CPB, air removal should be conducted at low LVAD speeds. 
The patient should be weaned off cardiopulmonary bypass or at minimal CPB support 
(approximately ≤1 liter/min) before increasing revolutions per minute speeds to permit 
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complete filling of the left ventricle (>10 mm Hg) and to prevent aspiration of air around the 
inflow conduit. The pump should be initiated at low speeds and increases made slowly. 
If right ventricle dysfunction occurs, resulting in poor LVAD inflow, temporary right-heart 
bypass can be used to provide blood flow to the LVAD while transitioning from CPB. For 
more profound right ventricle failure, a temporary RVAD should be considered and 
implemented expeditiously. Intraoperative echocardiography is essential for identifying 
valvular pathology, intracardiac thrombi, and an atrial septal defect or patent foramen ovale 
(PFO). A PFO should be closed at the time of implantation. Intracardiac thrombus identified 
in the left atria or ventricle should be removed before LVAD implantation. 
Echocardiography is critical for assessing left ventricle chamber size, cannula position, 
septal shifting, and aortic valve opening—factors used to determine optimal pump position 
and speed setting (Slaughter et al. 2010).  
10. Postoperative patient and device management 
A patient’s right ventricular function can be affected by pump speed. Avoid setting the pump 
speed so high that it causes a significant leftward septal shift and abnormal right ventricle 
geometry, which can adversely affect RV function. High pump speeds can also collapse the left 
ventricle and obstruct flow through the LVAD inlet cannula draining the left ventricle. 
Anticoagulation therapy is required during support with continuous-flow LVADs to avoid 
thrombotic complications. However, results from the HeartMate II Bridge to Transplant trial 
indicate that anticoagulation requirements for this therapy are less than was initially 
believed. The results from the clinical trial revealed that the incidence of thrombotic events 
is very low— much lower than bleeding—which remains one of the most frequent adverse 
events (Miller et al. 2007; Pagani et al. 2009). 
Routine use of heparin is not indicated immediately after the LVAD is implanted. However, 
there are some clinical conditions of higher thrombotic risk where postoperative heparin 
may be indicated in the transition to warfarin therapy, such as small patients who have low 
LVAD flow rates, a small ventricle, previous stroke or transient ischemic attack, chronic 
atrial fibrillation, or documented left atrial or left ventricle thrombus. Adequate hemostasis 
should be achieved before anticoagulation is initiated. Patients are usually anticoagulated 
with warfarin and antiplatelet agents (aspirin) when they are able to take oral medications. 
Current recommendations are to adjust the warfarin dose to achieve a target INR of 1.5 to 
2.5. In addition to warfarin, patients should also be given antiplatelet therapy, such as 
aspirin (81 to 325 mg daily). If LVAD flow remains low (<3.0 liters/min), consider 
increasing anticoagulation. If there is a risk of bleeding, decreasing the warfarin dose and 
increasing or maintaining antiplatelet medications is considered. Anticoagulation and 
antiplatelet therapy may need to be adjusted for some clinical conditions. Some types of 
infection, especially bacteremia, are associated with a higher incidence of stroke due to 
increased endothelial activation and platelet aggregation (Basra et al., 2009). 
Therefore, increased antiplatelet therapy may be warranted during systemic bacterial 
infections. 
The major hemodynamic effects of a continuous-flow LVAD are increases in diastolic 
pressure and flow (Myers et al., 2009).  
Because these devices pump continuously throughout the entire cardiac cycle, aortic flow is 
also present during diastole when normal pulsatile flow is absent. The pulse pressure is 
influenced by left ventricular contractility, intravascular volume, pre-load and after-load 
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pressure, and by pump speed. Owing to the reduced pulse pressure during continuous-flow 
LVAD support, it is often difficult to palpate a pulse and measure blood pressure accurately 
by the usual auscultatory or automated methods. After the arterial catheter is removed, the 
arterial blood pressure is most reliably assessed using Doppler and a sphygmomanometer. 
Arterial blood pressure might be controlled with vasoactive and inotropic medications and 
intravascular fluid volume management. The pump speed should not be adjusted to achieve a 
desired arterial blood pressure. The goal is to maintain the mean arterial blood pressure in the 
range of 70 to 80 mm Hg. It should not exceed 90 mm Hg. Unlike a pulsatile LVAD, the 
amount of cardiac output support by a continuous-flow pump is affected by the after-load, or 
systemic vascular resistance. Maintaining the mean arterial pressure in the desired range will 
optimize cardiac support. Hypertension is controlled to avoid decreased LVAD support and 
cardiac output as well as to avoid cerebrovascular events. Immobilizing the percutaneous lead 
to prevent exit site trauma reduces infection risk. Care of the percutaneous lead and exit site 
must be a priority for successful outpatient care (Slaughter et al. 2010). 
Multidisciplinary teams are required that allow close collaboration between cardiologists, 
medical specialists, and cardiac surgeons. The HF specialist must participate in managing 
these teams. The HF specialist should be familiar with the need to evaluate right ventricular 
function and associated tricuspid regurgitation prior to placement of an LVAD. Compared 
with successful cardiac transplantation, exercise capacity is lower following chronic 
outpatient mechanical support and the patient’s daily concerns are typically greater (e.g., 
battery exchange or recharging, driveline maintenance). A key point in postoperative device 
management is paying attention that continuous-flow LVADs do not contain valves. If the 
pump stops, there may be back flow, which can have severe consequences (similar to aortic 
insufficiency), so we must avoid power interruption or inadvertent power lead 
disconnection that would lead to loss of support. Pump speed optimization and device 
monitoring present unique challenges compared with pulsatile devices, because continuous-
flow pumps can generate large negative pressures at the pump inlet, which may result in 
septal shift or ventricular collapse. It is also important to avoid setting the pump speed too 
high, which can result in ventricular collapse or inlet obstruction and initiate arrhythmias 
(ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of 
Patients With Advanced Heart Failure and Cardiac Transplant). The system-provided 
parameters of speed, power, pulsatility index, and estimated flow in conjunction with 
echocardiography serve as the primary indicators of proper device function. The patient’s 
clinical status should always be assessed when device function is evaluated. 
Successful long-term LVAD support depends on comprehensive care from a 
multidisciplinary team, including the patient and his or her family member(s)/caregiver(s). 
Training on proper self-care and system operation, with an emphasis on meticulous care of 
the percutaneous lead and exit site, should begin preoperatively. Training continues 
throughout hospitalization. Eventually, the patient’s demonstration of understanding and 
competency may be a requirement for discharge. 
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